Published in Cancer Res on December 04, 2014
TPX2 Level Correlates with Hepatocellular Carcinoma Cell Proliferation, Apoptosis, and EMT. Dig Dis Sci (2015) 0.90
Armored long non-coding RNA MEG3 targeting EGFR based on recombinant MS2 bacteriophage virus-like particles against hepatocellular carcinoma. Oncotarget (2016) 0.88
The Cytokinome Profile in Patients with Hepatocellular Carcinoma and Type 2 Diabetes. PLoS One (2015) 0.85
The mutational landscape of hepatocellular carcinoma. Clin Mol Hepatol (2015) 0.82
HBP1-mediated Regulation of p21 Protein through the Mdm2/p53 and TCF4/EZH2 Pathways and Its Impact on Cell Senescence and Tumorigenesis. J Biol Chem (2016) 0.80
p53, a potential predictor of Helicobacter pylori infection-associated gastric carcinogenesis? Oncotarget (2016) 0.79
MicroRNA-98 acts as a tumor suppressor in hepatocellular carcinoma via targeting SALL4. Oncotarget (2016) 0.79
Association between MDM2 rs769412 and rs937283 polymorphisms with alcohol drinking and laryngeal carcinoma risk. Int J Clin Exp Pathol (2015) 0.79
Novel Investigations of Flavonoids as Chemopreventive Agents for Hepatocellular Carcinoma. Biomed Res Int (2015) 0.78
TRIM11, a direct target of miR-24-3p, promotes cell proliferation and inhibits apoptosis in colon cancer. Oncotarget (2016) 0.78
Expression of P53 and HSP70 in Chronic Hepatitis, Liver Cirrhosis, and Early and Advanced Hepatocellular Carcinoma Tissues and Their Diagnostic Value in Hepatocellular Carcinoma: An Immunohistochemical Study. Med Sci Monit (2015) 0.77
Emerging roles of FGF signaling in hepatocellular carcinoma. Transl Cancer Res (2016) 0.76
Novel MDM2 inhibitor SAR405838 (MI-773) induces p53-mediated apoptosis in neuroblastoma. Oncotarget (2016) 0.76
Downregulation of cyclin D1 sensitizes cancer cells to MDM2 antagonist Nutlin-3. Oncotarget (2016) 0.76
NORE1A Regulates MDM2 Via β-TrCP. Cancers (Basel) (2016) 0.75
CDKN3 expression is negatively associated with pathological tumor stage and CDKN3 inhibition promotes cell survival in hepatocellular carcinoma. Mol Med Rep (2016) 0.75
Association of RNF43 with cell cycle proteins involved in p53 pathway. Int J Clin Exp Pathol (2015) 0.75
Biphasic and Stage-Associated Expression of CPEB4 in Hepatocellular Carcinoma. PLoS One (2016) 0.75
Histone deacetylase inhibitor sodium butyrate suppresses proliferation and promotes apoptosis in osteosarcoma cells by regulation of the MDM2-p53 signaling. Onco Targets Ther (2016) 0.75
Dynamics of p53: A Master Decider of Cell Fate. Genes (Basel) (2017) 0.75
Activation of PERK-Nrf2 oncogenic signaling promotes Mdm2-mediated Rb degradation in persistently infected HCV culture. Sci Rep (2017) 0.75
Stress Hormone Cortisol Enhances Bcl2 Like-12 Expression to Inhibit p53 in Hepatocellular Carcinoma Cells. Dig Dis Sci (2017) 0.75
Overexpression of Protein Phosphatase 1γ (PP1γ) Is Associated with Enhanced Cell Proliferation and Poor Prognosis in Hepatocellular Carcinoma. Dig Dis Sci (2016) 0.75
Murine double minute 2, a potential p53-independent regulator of liver cancer metastasis. Hepatoma Res (2016) 0.75
Reviving the guardian of the genome: Small molecule activators of p53. Pharmacol Ther (2017) 0.75
Global cancer statistics. CA Cancer J Clin (2011) 185.92
Hallmarks of cancer: the next generation. Cell (2011) 140.01
Senescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas. Nature (2007) 16.95
The IARC TP53 database: new online mutation analysis and recommendations to users. Hum Mutat (2002) 12.39
Small molecule RITA binds to p53, blocks p53-HDM-2 interaction and activates p53 function in tumors. Nat Med (2004) 5.48
p53 mutations in cancer. Nat Cell Biol (2013) 5.18
Ribosomal protein L23 activates p53 by inhibiting MDM2 function in response to ribosomal perturbation but not to translation inhibition. Mol Cell Biol (2004) 4.08
Temporal activation of p53 by a specific MDM2 inhibitor is selectively toxic to tumors and leads to complete tumor growth inhibition. Proc Natl Acad Sci U S A (2008) 4.07
Signaling to p53: ribosomal proteins find their way. Cancer Cell (2009) 3.84
The MDM2-p53 interaction. Mol Cancer Res (2003) 3.43
Inhibition of HDM2 and activation of p53 by ribosomal protein L23. Mol Cell Biol (2004) 3.31
p53 Antibodies in the sera of patients with various types of cancer: a review. Cancer Res (2000) 3.31
The inherent instability of mutant p53 is alleviated by Mdm2 or p16INK4a loss. Genes Dev (2008) 3.17
Structure-based design of spiro-oxindoles as potent, specific small-molecule inhibitors of the MDM2-p53 interaction. J Med Chem (2006) 2.95
TP53 mutations and hepatocellular carcinoma: insights into the etiology and pathogenesis of liver cancer. Oncogene (2007) 2.71
p53: new roles in metabolism. Trends Cell Biol (2007) 2.69
p53 and its mutants in tumor cell migration and invasion. J Cell Biol (2011) 2.49
Non-cell-autonomous tumor suppression by p53. Cell (2013) 2.40
An N-terminal p14ARF peptide blocks Mdm2-dependent ubiquitination in vitro and can activate p53 in vivo. Oncogene (2000) 2.36
Energy deregulation: licensing tumors to grow. Science (2006) 2.31
p53 protein stability in tumour cells is not determined by mutation but is dependent on Mdm2 binding. Oncogene (1997) 2.31
Metabolic syndrome and hepatocellular carcinoma: two growing epidemics with a potential link. Cancer (2009) 2.19
Small molecule inhibitors of HDM2 ubiquitin ligase activity stabilize and activate p53 in cells. Cancer Cell (2005) 2.17
Molecular mechanism of the interaction between MDM2 and p53. J Mol Biol (2002) 2.03
After a decade of study-ING, a PHD for a versatile family of proteins. Trends Biochem Sci (2007) 2.00
Downregulation of KLF6 is an early event in hepatocarcinogenesis, and stimulates proliferation while reducing differentiation. J Hepatol (2006) 1.98
Activation and activities of the p53 tumour suppressor protein. Br J Cancer (2001) 1.90
The p53 family and programmed cell death. Oncogene (2008) 1.81
Global cancer patterns: causes and prevention. Lancet (2013) 1.67
Benzodiazepinedione inhibitors of the Hdm2:p53 complex suppress human tumor cell proliferation in vitro and sensitize tumors to doxorubicin in vivo. Mol Cancer Ther (2006) 1.37
Hepatic IGFBP1 is a prosurvival factor that binds to BAK, protects the liver from apoptosis, and antagonizes the proapoptotic actions of p53 at mitochondria. Genes Dev (2007) 1.37
Hepatic steatosis is associated with increased frequency of hepatocellular carcinoma in patients with hepatitis C-related cirrhosis. Cancer (2007) 1.30
Targeting p53 for Novel Anticancer Therapy. Transl Oncol (2010) 1.26
Reactivation of p53: from peptides to small molecules. Trends Pharmacol Sci (2010) 1.25
MDM2 and p53 polymorphisms are associated with the development of hepatocellular carcinoma in patients with chronic hepatitis B virus infection. Carcinogenesis (2008) 1.25
The Warburg effect version 2.0: metabolic reprogramming of cancer stem cells. Cell Cycle (2013) 1.20
The balance between rRNA and ribosomal protein synthesis up- and downregulates the tumour suppressor p53 in mammalian cells. Oncogene (2011) 1.13
Expression of the serum response factor in hepatocellular carcinoma: implications for epithelial-mesenchymal transition. Int J Oncol (2007) 1.13
MDM2 promoter SNP309 is associated with the risk of hepatocellular carcinoma in patients with chronic hepatitis C. Clin Cancer Res (2006) 1.12
Carcinogen-induced hepatic tumors in KLF6+/- mice recapitulate aggressive human hepatocellular carcinoma associated with p53 pathway deregulation. Hepatology (2011) 1.07
Sirt3 inhibits hepatocellular carcinoma cell growth through reducing Mdm2-mediated p53 degradation. Biochem Biophys Res Commun (2012) 1.06
Chemotherapy-induced apoptosis in hepatocellular carcinoma involves the p53 family and is mediated via the extrinsic and the intrinsic pathway. Int J Cancer (2010) 1.05
p53 regulates a mitotic transcription program and determines ploidy in normal mouse liver. Hepatology (2013) 1.05
p53-dependent Nestin regulation links tumor suppression to cellular plasticity in liver cancer. Cell (2014) 1.04
Differentiation of Hdm2-mediated p53 ubiquitination and Hdm2 autoubiquitination activity by small molecular weight inhibitors. Proc Natl Acad Sci U S A (2002) 1.03
Correlation between expression of p53, p21/WAF1, and MDM2 proteins and their prognostic significance in primary hepatocellular carcinoma. J Transl Med (2009) 1.00
p53 gene in treatment of hepatic carcinoma: status quo. World J Gastroenterol (2007) 0.95
Human inhibitor of growth 1 inhibits hepatoma cell growth and influences p53 stability in a variant-dependent manner. Hepatology (2009) 0.94
Recent advancements in comprehensive genetic analyses for human hepatocellular carcinoma. Oncology (2013) 0.93
Enigma negatively regulates p53 through MDM2 and promotes tumor cell survival in mice. J Clin Invest (2010) 0.91
Post-transcriptional modulation of iron homeostasis during p53-dependent growth arrest. J Biol Chem (2008) 0.90
Anti-tumor efficacy of a novel antisense anti-MDM2 mixed-backbone oligonucleotide in human colon cancer models: p53-dependent and p53-independent mechanisms. Mol Med (2002) 0.90
New p53 target, phosphatase of regenerating liver 1 (PRL-1) downregulates p53. Oncogene (2008) 0.90
p53 and the regulation of hepatocyte apoptosis: implications for disease pathogenesis. Trends Mol Med (2009) 0.89
Serum p53 protein and anti-p53 antibodies are associated with increased cancer risk: a case-control study of 569 patients and 879 healthy controls. Mol Biol Rep (2009) 0.88
Iron-dependent regulation of MDM2 influences p53 activity and hepatic carcinogenesis. Am J Pathol (2009) 0.88
p53 gene mutations and 17p allelic deletions in hepatocellular carcinoma from Japan. Cancer (1993) 0.85
Characterization, chemical optimization and anti-tumour activity of a tubulin poison identified by a p53-based phenotypic screen. Cell Cycle (2008) 0.85
Stem cells in a three-dimensional scaffold environment. Springerplus (2014) 0.85
Combination of radiotherapy and adenovirus-mediated p53 gene therapy for MDM2-overexpressing hepatocellular carcinoma. J Radiat Res (2012) 0.83
A rare case of isolated duodenal metastases from hepatocellular carcinoma associated with p53 and ki-67 expression: a case report. Cases J (2009) 0.81
Gene p53 mutations, protein p53, and anti-p53 antibodies as biomarkers of cancer process. Int J Occup Med Environ Health (2002) 0.79
Novel amino-modified silica nanoparticles as efficient vector for hepatocellular carcinoma gene therapy. Med Oncol (2009) 0.78
Reactivation of p53 in cells expressing hepatitis B virus X-protein involves p53 phosphorylation and a reduction of Hdm2. Cancer Sci (2008) 0.78